Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,242.00
(
0.45%
)
Dow Jones
46,993.26
(
0.00%
)
Brent Oil
101.92
(
1.26%
)
Bitcoin
72,709.00
(
-1.67%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

NP1986

Send PM Follow Ignore
Followers 6
Posts 541
Boards Moderated 0
Alias Born 06/07/2011

NP1986

Re: DewDiligence post# 150773

Wednesday, 10/17/2012 2:06:29 PM

Wednesday, October 17, 2012 2:06:29 PM

Post# of 257253
What are your reasons for speculating that Rituxan is not one of the first three FoBs in the MNTA/BAX agreement?

If they are indeed confident of being able to develop interchangeable FoBs, then Rituxan would seem to be an obvious choice. Even with the availability of non-interchangeable FoBs, Rituxan could still be a blockbuster product - unless you believe that biobetters such as obinutuzumab will supplant Rituxan.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now